Enforced Data Collection on Brain Tumors

Publication
Article
OncologyONCOLOGY Vol 16 No 1
Volume 16
Issue 1

Legislation that would force all states to collect data on benign brain tumors got a hearing before a House subcommittee in mid-November. That was the critical first step needed before Rep. Barbara Lee (D-Calif), the measure’s sponsor, could

Legislation that would force all states tocollect data on benign brain tumors got a hearing before a House subcommittee inmid-November. That was the critical first step needed before Rep. Barbara Lee(D-Calif), the measure’s sponsor, could start pushing her bill throughCongress. Rep. Lee’s bill (H.R. 239) would make it mandatory for all states tocollect data on the incidence of primary brain tumors (whether malignant orbenign) in their state registries. Those registries get funding from, and passtheir data along to, the Centers for Disease Control and Prevention (CDC) viathat agency’s National Program of Cancer Registries. 

The CDC spent about $36million in fiscal 2001. At present, 21 state registries already collectmalignant brain tumor data, but the other 29 do not. Rep. Lee estimates that theCDC would have to spend an additional $1 million to prod the 29 states tocollect the desired data.

Brain tumors are the second leading cause of cancer death inchildren as well as the third leading cause of cancer death in young adults aged15 to 34 years, although approximately half of all brain tumors are consideredbenign. Nationwide, the incidence of brain tumors has increased by 25% since1975, for unknown reasons. Survival rates in women diagnosed with so-calledbenign meningiomas are lower than those for women with breast cancer.

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
Related Content